A5033616609- Renal cell carcinoma treatment
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Statistical Methods in Clinical Trials
- Pneumonia and Respiratory Infections
- Monoclonal and Polyclonal Antibodies Research
- Antibiotic Resistance in Bacteria
- Antibiotics Pharmacokinetics and Efficacy
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Analytical Chemistry and Chromatography
- Chronic Kidney Disease and Diabetes
- Chronic Myeloid Leukemia Treatments
- HIV/AIDS drug development and treatment
- Renal and related cancers
- Medication Adherence and Compliance
- Environmental Monitoring and Data Management
- PI3K/AKT/mTOR signaling in cancer
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Metabolomics and Mass Spectrometry Studies
- HER2/EGFR in Cancer Research
- Gene expression and cancer classification
- Chemotherapy-induced organ toxicity mitigation
Université Toulouse III - Paul Sabatier
2018-2024
Centre de Recherche en Cancérologie de Toulouse
2019-2024
Inserm
2018-2024
Institut universitaire du cancer de Toulouse Oncopole
2019-2024
Institut Claudius Regaud
2019-2024
Université de Toulouse
2018-2023
Determining dihydropyrimidine dehydrogenase (DPD) activity by measuring patient's uracil (U) plasma concentration is mandatory before fluoropyrimidine (FP) administration in France. In this study, we aimed to refine the pre-analytical recommendations for determining U and dihydrouracil (UH2 ) concentrations, as they are essential reliable DPD-deficiency testing.U UH2 concentrations were collected from 14 hospital laboratories. Stability whole blood after centrifugation, type of anticoagulant...
Pharmacokinetic (PK) parameter estimation is a critical and complex step in the model-informed precision dosing (MIPD) approach. The mapbayr package was developed to perform maximum posteriori Bayesian (MAP-BE) R from any population PK model coded mrgsolve. performances of were assessed using two approaches. First, "test" models with different features coded, for example, first-order zero-order absorption, lag time, time-varying covariates, Michaelis-Menten elimination, combined exponential...
Aims Cetuximab associated with cisplatin and 5‐fluorouracil is used to treat patients inoperable or metastatic head neck squamous cell carcinomas (HNSCC) up until disease progression unacceptable toxicities. To date, no biomarkers of efficacy are available select who will benefit from treatment. Methods An ancillary pharmacokinetics (PK) exploration was performed in the context a prospective study investigating circulating‐tumour cells vs progression‐free survival (PFS). plasma...
Therapeutic drug monitoring of ibrutinib is based on the area under curve concentration vs. time (AUCIBRU) instead trough (Cmin,ss) because a limited accumulation in plasma. Our objective was to identify sampling strategy (LSS) estimate AUCIBRU associated with Bayesian estimation. The actual 85 patients determined by analysis full pharmacokinetic profile concentrations (pre-dose T0 and 0.5, 1, 2, 4 6 h post-dose) experimental were derived considering combinations one four times. T0–1–2–4...
Hepatotoxicity is an important concern for nearly 40% of the patients treated with trabectedin advanced soft tissue sarcoma (ASTS). The mechanisms underlying these liver damages have not yet been elucidated but they suggested to be related production reactive metabolites. aim this pharmacogenetic study was identify genetic variants pharmacokinetic genes such as CYP450 and ABC drug transporters that could impair metabolism in hepatocytes. Sixty-three ASTS from TSAR clinical trial...
Background: Conditioning bifunctional agent, busulfan, is commonly used on children before hematopoietic stem cell transplantation. Currently, at the Ramathibodi hospital, Bangkok, Thailand, initial dosing calculated according to age and body surface area, 7 samples per day are for therapeutic drug monitoring (TDM). This study aimed identify best strategies individual dosages a priori from patient characteristics posteriori based TDM. Methods: The pharmacokinetic data set consisted of 2018...
To rapidly achieve ceftazidime target concentrations, a 2 g loading dose (LD) is recommended before continuous infusion, but its adequacy in critically ill patients, given their unique pharmacokinetics, needs investigation. This study included patients from six ICUs Saint-Etienne and Paris, France, who received infusion with plasma concentration measurements. Using MONOLIX R, pharmacokinetic (PK) model was developed, the literature on ICU patient PK models reviewed. Simulations calculated LD...
Aims Dose‐banding (DB) consists in approximating the theoretical dose of anticancer drugs calculated according to body surface area (Dose‐BSA) patients. This concept is supported by pharmacokinetic but not clinical data. The aim this study was assess outcome DB defined as dose‐fitting up ±10%. Methods a retrospective conducted patients receiving weekly paclitaxel neoadjuvant (NAT) and metastatic (M+) settings. Three groups were considered type dosing: Dose‐BSA, approximated down (DB‐Low)...
Abstract Background In order to rapidly achieve target concentrations and bactericidal efficacy, the administration of a loading dose (LD) is recommended before starting ceftazidime continuous infusion. However, adequacy 2g-LD usually administered should be investigated considering special pharmacokinetic characteristics critically ill patients. Materials PK dataset for model development external validation included patients hospitalized in 6 intensive care units (ICU) Saint-Etienne region...